[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"squamous-cell-non-small-cell-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:squamous-cell-non-small-cell-lung-cancer":131},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,56,89,117,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100437528","phase-1-gi-101gi-101a-as-a-single-agent-or-in-combination-with-pembrolizumab-or-lenvatinib-in-advanced-solid-tumors-100437528",false,"NCT04977453","GI-101\u002FGI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","A Phase 1\u002F2, Open-label, Dose-escalation, Dose-optimization and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101\u002FGI-101A as a Single Agent and in Combination With Pembrolizumab or Lenvatinib in Patients With Advanced or Metastatic Solid Tumors (Keynote B59)","Key Inclusion Criteria:\n\n* Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening.\n* Has adequate organ and marrow function as defined in protocol.\n* Measurable disease as per RECIST v1.1.\n* ECOG performance status 0-1.\n* Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy, other prior systemic anti-cancer therapy, or surgery must have resolved to Grade ≤1, except alopecia and Grade 2 peripheral neuropathy.\n* HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection\u002Fdisease as defined in protocol.\n\nKey Exclusion Criteria:\n\n* Has known active CNS metastases and\u002For carcinomatous meningitis.\n* An active second malignancy\n* Has active or a known history of Hepatitis B or known active Hepatitis C virus infection.\n* Has active tuberculosis or has a known history of active tuberculosis\n* Active or uncontrolled infections, or severe infection within 4 weeks before study treatment administration.\n* History of chronic liver disease or evidence of hepatic cirrhosis, except patients with liver metastasis.\n* Has an active autoimmune disease that has required systemic treatment in past 2 years.\n* Previous immunotherapies related to mode of action of GI-101.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive medications within 2 weeks prior to Cycle 1 Day 1.\n* Administration of prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.\n* Radiotherapy within the last 2 weeks before start of study treatment administration, with exception of limited field palliative radiotherapy\n* Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1.\n* Known hypersensitivity to any of the components of the drug products and\u002For excipients of GI-101\u002FGI-101A, pembrolizumab or lenvatinib.\n\nOther protocol defined inclusion exclusion criteria may apply. Cancer type and part-specific inclusion criteria are described in the study protocol.","ALL","18 Years",{"count":19,"type":20},317,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101\u002FGI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and\u002For metastatic solid tumors.",[27,28,29,30,31,32],"Advanced Solid Tumor","Metastatic Solid Tumor","Cervical Cancer","Urothelial Carcinoma","Clear Cell Renal Cell Cancer (ccRCC)","Squamous Cell Non Small Cell Lung Cancer",[34,35,36,37,38,39,40,41,42],"GI-101\u002FGI-101A","CD80-IgG4 Fc-IL2 variant","Immunotherapy","IL-2","Interleukin-2","Pembrolizumab","Lenvatinib","CPI-refractory","Immunocytokine","RECRUITING","2026-05-13",{"date":46,"type":47},"2026-05-15","ACTUAL",{"date":49,"type":47},"2021-08-02",{"date":51,"type":20},"2028-06-30",{"name":53,"class":54},"GI Innovation, Inc.","INDUSTRY",12,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":21,"phases":65,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100605576","phase-1-a-study-of-zw251-in-participants-with-advanced-solid-tumors-100605576","NCT07164313","A Study of ZW251 in Participants With Advanced Solid Tumors","A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and\u002For metastatic disease. Noninvasive methods may be used to confirm diagnosis\n* Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and\u002For metastatic disease\n* Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and\u002For choriocarcinoma predominant component and locally advanced (unresectable) and\u002For metastatic disease\n* Measurable disease per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Liver function status of Child-Pugh Class A (for HCC only)\n* Adequate organ function\n\nExclusion Criteria:\n\n* Known additional malignancy that is progressing or that has required active treatment within the last year\n* History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy\n* Participants with HCC experiencing main portal vein tumor invasion require sponsor approval for enrollment\n* Known gastrointestinal bleeding within 3 months\n* Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease",{"count":64,"type":20},100,[23],"The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).",[68,69,70],"Hepatocellular Carcinoma","Squamous Cell Non-Small Cell Lung Cancer","Germ Cell Tumor",[72,73,74,75,76,77,78,70],"GPC3-expressing cancer","hepatocellular carcinoma","antibody drug conjugate","ADC","Lung Cancer","Non-Small Cell Lung Cancer","Squamous Cell Cancer","2026-05-05",{"date":81,"type":47},"2026-05-07",{"date":83,"type":47},"2025-10-21",{"date":85,"type":20},"2028-05",{"name":87,"class":54},"Zymeworks BC Inc.",25,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100582092","phase-1-a-study-to-assess-adverse-events-and-change-in-disease-activity-of-intravenously-iv-infused-abbv-324-in-adult-participants-with-hepatocellular-cancer-hcc-or-squamous-cell-non-small-cell-lung-cancer-lusc-100582092","NCT06858813","A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)","A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Hepatocellular cancer (HCC) only: Child-Pugh A classification within 7 days before Cycle 1, Day 1 dosing.\n* Laboratory values meeting the criteria outlined in the protocol.\n* QT interval corrected for heart rate (QTc) \\\u003C 470 msec (using Fridericia's correction), no Grade 3 arrythmia, and no other clinically significant cardiac abnormalities.\n* Measurable disease per RECIST version 1.1.\n* Part 1 and Part 2 - participants with HCC meeting the following disease activity criteria:\n\n  * Locally advanced or metastatic and\u002For unresectable HCC with diagnosis confirmed by histology or cytology. Participants with fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma\u002FHCC are not eligible to enroll.\n  * Disease that is not amenable to surgical and\u002For locoregional therapies, or progressive disease after surgical and\u002For locoregional therapies. For participants who progressed after locoregional therapy for HCC, locoregional therapy must have been completed \\>= 28 days prior to baseline scan for the current study.\n  * Part 1: Failure of at least 1 prior systemic treatment for HCC.\n  * Part 2: Failure of at least 1 prior systemic treatment consisting of an immune checkpoint inhibitor (CPI) containing regimen for HCC, including but not limited to, atezolizumab in combination with bevacizumab or tremelimumab in combination with durvalumab. Note: Participants who have received prior lenvatinib will not be eligible for Part 2.\n* Part 1 only - participants with squamous-cell non-small cell lung cancer (LUSC) meeting the following disease activity criteria:\n\n  * Advanced or metastatic LUSC that is not amenable to surgical resection.\n  * Must have failed at least 1 prior line of therapy that included at least platinum-based chemotherapy and an immune CPI, and\u002For an appropriate targeted therapy (if applicable), or is not suitable for other approved therapeutic options that have demonstrated clinical benefit at the judgment of the investigator. Participants should have no more than 2 lines of prior cytotoxic chemotherapy excluding neoadjuvant and\u002For adjuvant. Participants who are intolerant of standard therapy are eligible.\n\nExclusion Criteria:\n\n* Unresolved clinically significant adverse events (AEs) \\> Grade 1 from prior anticancer therapy except for alopecia.\n* Untreated brain or meningeal metastases (i.e., participants with history of metastases are eligible provided they do not require ongoing steroid treatment for cerebral edema and have shown clinical and radiographic stability for at least 14 days after definitive therapy). Participants may continue with antiepileptic therapy if required.\n* History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.\n* History of clinically significant, intercurrent lung-specific illnesses including, but not limited to:\n\n  * Underlying pulmonary disorder (i.e., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion, dependence on supplemental oxygen, etc.).\n  * Any autoimmune, connective tissue or inflammatory disorders with documented or suspicious pulmonary involvement at Screening.\n* Must have discontinued anticancer therapy with antineoplastic intent including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 14 days or 5 half lives of the drug (whichever is shorter) prior to the first dose of ABBV-324. Palliative radiation therapy for bone, skin or subcutaneous metastases with 10 fractions or less is permitted and not participant to a washout period.",{"count":97,"type":20},232,[23],"HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths. The purpose of this study is to assess adverse events and change in disease activity when ABBV-324 is given to adult participants to treat hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC).\n\nABBV-324 is an investigational drug being developed for the treatment of HCC and LUSC. Study doctors put the participants in groups called arms. Each arm receives ABBV-324 alone (monotherapy) or a comparator drug, lenvatinib followed by a safety follow-up period. Approximately 232 HCC or LUSC will be enrolled in the study in approximately 45 sites worldwide.\n\nIn the dose escalation stage participants will be treated with increasing intravenous (IV) doses of ABBV-324 until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will receive ABBV-324, or a comparator of oral lenvatinib. The study will run for a duration of approximately 6.5 years.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.",[101,102],"Hepatocellular Cancer","Squamous-Cell Non-Small Cell Lung Cancer",[101,102,104,105,106,40],"LUSC","HCC","ABBV-324","2026-03-23",{"date":109,"type":47},"2026-03-25",{"date":111,"type":47},"2025-04-14",{"date":113,"type":20},"2030-09",{"name":115,"class":54},"AbbVie",22,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100540628","phase-2-efficacy-and-safety-of-jmt101-combined-wth-docetaxel--hb1801-in-patients-with-squamous-cell-non-small-cell-lung-cancer-100540628","NCT06319313","Efficacy and Safety of JMT101 Combined Wth Docetaxel \u002F HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer","A Randomized, Controlled, Open-label Phase II\u002FIII Study of The Safety, Tolerability and Efficacy of JMT101 Combined With Docetaxel \u002F HB1801 in Patients With sqNSCLC","Inclusion Criteria:\n\n1. Age ranged from 18 to 75 years old (inclusive), regardless of gender;\n2. Pathological diagnosis as sqNSCLC, with EGFR highly expressed, without other driver genes\n3. Tumor tissue available for central laboratory testing;\n4. Disease progression after prior anti PD-1\u002FPD-L1 and platinum containing chemotherapy\n5. Measurable disease according to RECIST1.1;\n6. Eastern Cooperative Oncology Group (ECOG) score 0-1 points;\n7. Life expectancy ≥3 months\n8. Adequate main organs and bone marrow function.\n9. Patients must give informed consent to this study before the experiment and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Previously used anti EGFR, or docetaxel;\n2. Central nervous system metastasis or meningeal metastasis;\n3. Patients with high risk of bleeding due to tumor invasion of important arteries;\n4. Uncontrolled or requiring repeated drainage of pleural effusion, pericardial effusion, or abdominal effusion;\n5. The adverse reactions of previous anti-tumor treatments (including radiotherapy) have not yet recovered to CTCAE 5.0 evaluation ≤ level 1 except for toxicity such as alocepia or fatigue, which is judged to be of no safety risk by researchers;\n6. Diagnosed as a second primary malignant tumor (except for skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ and breast carcinoma in situ, etc.) within 5 years prior to the first administration of the study drug;\n7. Have received anti-tumor treatments such as systemic chemotherapy, biological therapy, immunotherapy, radical radiotherapy chemotherapy, etc. within 28 days before the first dose of the study drug;\n8. Have undergone major surgery (excluding needle biopsy) or suffered severe traumatic injury within 28 days before the first dose of study drug;\n9. Have received a live viral vaccine or live-attenuated vaccine within 28 days before the first dose of study drug or plan to receive it during the study;\n10. Have received palliative radiotherapy, small molecule targeted therapy, immunomodulatory drugs, NMPA approved modern traditional Chinese medicine preparations and other anti-tumor treatments, within 14 days before the first dose of study drug;\n11. Those who use strong CYP3A4 inducers within 14 days before the first administration of the study drug, or those who use strong CYP3A4 inhibitors within 1 week, or those who cannot suspend the use of the above drugs during the study;\n12. Have a history of serious cardiovascular disease;\n13. Have a history of serious lung disease;\n14. History of autoimmune diseases;\n15. History of immunodeficiency\n16. A history of gastrointestinal perforation and\u002For fistula within 6 months, or gastrointestinal obstruction and active inflammatory bowel disease within 28 days prior to the first study drug administration\n17. Have infectious diseases requiring systemic anti-infective treatment;\n18. Active hepatitis B; hepatitis C infection; syphilis infection, active tuberculosis;\n19. Known hypersensitivity or intolerance to any component of EGFR monoclonal antibody, human serum albumin, docetaxel, and its excipients; Individuals known to be allergic and\u002For contraindicated to glucocorticoids\n20. Women during lactation or pregnancy;\n21. Any male and female patients with fertility who refuse to use effective contraceptive methods throughout the entire trial period and within six months after the last administration;\n22. Other conditions that, in the opinion of the investigator, may affect the safety or compliance of drug treatment in this study, including but not limited to: psychiatric disorders, any severe or uncontrollable diseases, etc.","75 Years",{"count":126,"type":20},534,[24,128],"PHASE3","This study is a phase II\u002FIII, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel\u002F HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）.",[131],"Squamous Cell Non-small Cell Lung Cancer","NOT_YET_RECRUITING","2024-03-18",{"date":135,"type":47},"2024-03-20",{"date":137,"type":20},"2024-05-01",{"date":139,"type":20},"2027-12-01",{"name":141,"class":54},"Shanghai JMT-Bio Inc.",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":169},"100472252","phase-3-neoadjuvant-therapy-of-sintilimab-combined-with-chemotherapy-for-resectable-squamous-cell-nsclcneoscore--100472252","NCT05429463","Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）","Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）：A Prospective, Randomized, Open-Label, Multi-Center Phase 3 Trial","neoSCORE Ⅱ","Inclusion Criteria:\n\n1. Sign the informed consent form before starting any trial related procedure.Be willingness and able to undergo planned visits, protocol therapy, laboratory tests and other testing procedures.\n2. 18-75 years old, male or female.\n3. Squamous Cell Non-small cell lung cancer confirmed by cytology or histology.\n4. There must be at least one evaluable focus judged according to recist1.1 standard.\n5. Evaluation by the researchers and classified by the 8th version of AJCC TNM staging to confirm resectable stage cⅡA-ⅢB squamous NSCLC patients without any treatment before.\n6. ECOG PS 0-1.\n7. Life expectancy \\> 6 months.\n8. Adequate organ function and it should meet the following criteria:\n\n   Absolute value of neutrophils (ANC) ≥1.5×109\u002FL in the absence of granulocyte colony stimulating factor for the past 14 days; Platelet ≥100×109\u002FL in the last 14 days without blood transfusion; Hemoglobin \\>9g\u002FdL in the absence of blood transfusion or erythropoietin in the last 14 days ;\n\n   Total bilirubin(TBIL)≤1.5ULN, ALT、AST≤ 2.5 ULN, serum creatinine(sCr)≤1.5ULN;\n\n   Good blood coagulation: INR≤1.5 or PT≤1.5 ULN;\n\n   Normal thyroid function: TSH within normal institutional limits;\n9. For women of reproductive age, a urine or serum pregnancy test with negative results should be performed within 3 days prior to receiving the first study drug administration (day 1 of cycle 1). If a urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is requested. Women of nonreproductive age were defined as at least 1 year after menopause or having undergone surgical sterilization or hysterectomy. If there is a risk of conception, all subjects (both men and women) will use a medically approved highly effective contraceptive (e.g., an intrauterine device, birth control pill, or condom) for the entire treatment period up to 120 days after the last study drug (or 180 days after the last chemotherapy drug).\n\nExclusion Criteria:\n\n1. Malignancies within 5 years prior to the first dose(excluding radical skin basal cell carcinoma, skin squamous cell carcinoma and \u002F or radical resection of carcinoma in situ).\n2. Currently participating in the intervention clinical treatment, or receiving other drugs or research instruments within 4 weeks before the first dose.\n3. Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or drugs for another stimulation or synergistic inhibition of T cell receptor (e.g. CTLA-4, OX-40, CD137).\n4. Active autoimmune diseases requiring systemic treatment (e.g. using disease improving drugs, corticosteroids or immunosuppressants) occurred within 2 years before the first dose. Alternative therapies (e.g. thyroxine, insulin or corticosteroids in physiological doses for adrenal or pituitary insufficiency) are not considered systemic treatment.\n5. Systemic glucocorticoid therapy (excluding local glucocorticoids by nasal spray, inhalation or other routes) or any other form of immunosuppressive therapy is in progress within 7 days before the first dose.\n\n   Note: it is allowed to use physiological dose of glucocorticoid (Prednisone≤10 mg\u002Fd or equivalent drug).\n6. Received allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.\n7. Allergic to study drug(sintilimab, carboplatin, albumin-bound paclitaxel) components excipients.\n8. Not fully recovered from toxicity and\u002F or complications caused by any intervention before treatment (≤level 1 or reach baseline, excluding fatigue or hair loss).\n9. Has a known history of human immunodeficiency virus (HIV) infection (HIV 1\u002F2 antibody positive).\n10. Untreated active Hepatitis B (defined as HBsAg positive and HBV-DNA copies\\>ULN).\n11. Active Hepatitis C (HCV antibody positive and HCV-RNA level higher than the detection limit).\n12. Inoculate the live vaccine within 30 days before the first dose (cycle 1 day 1).\n\n    Note: it is allowed to receive the injection inactivated virus vaccine for seasonal influenza within 30 days before the first dose; however, it is not allowed to accept the live attenuated influenza vaccine for intranasal medication.\n13. Pregnant or lactating women.\n14. There are any serious or uncontrollable systemic diseases, such as:\n\n    Resting ECG has significant abnormalities in rhythm, conduction or morphology, and the symptoms are serious and difficult to control,such as complete left bundle branch block, heart block above degree Ⅱ, ventricular arrhythmia or atrial fibrillation;\n\n    Unstable angina, congestive heart failure, chronic heart failure with NYHA grade ≥ 2;\n\n    Within 6 months before inclusion, there were any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack etc;\n\n    History of noninfectious pneumonia requiring glucocorticoid treatment within 1 year before the first dose,or having currently clinical active interstitial lung diseases;\n\n    Active pulmonary tuberculosis;\n\n    Active or uncontrolled infections requiring systemic treatment;\n\n    Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;\n\n    Poorly controlled diabetes (Fasting blood glucose (FBG)\\>10mmol\u002FL);\n\n    Urine routine test indicates that urine protein≥++, and confirmed that 24 hours proteinuria\\>1.0 g;\n\n    Patients with mental disorders who are unable to cooperate with the treatment;\n15. There are medical history, disease, treatment or laboratory abnormal results that may interfere with the test results, prevent the subjects from participating in the whole process of the study, or the researchers think that participating in the study is not in the best interests of the subjects or there are other potential risks that the subjects are not suitable for the study.",{"count":151,"type":20},250,[128],"This is a Phase 3, prospective, randomized, open-label, multi-center study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for Resectable Squamous Cell NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.",[131],[156,157,158],"Sintilimab","Squamous Cell NSCLC","Neoadjuvant immunochemotherapy","2022-12-13",{"date":161,"type":47},"2022-12-14",{"date":163,"type":47},"2022-11-11",{"date":165,"type":20},"2029-11-11",{"name":167,"class":168},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1]